Home Latest Articles
Latest Articles
  • Yuan LIU
    World Clinical Drug. 2024, 45(5): 454-458.

    Glucocorticoid (GC) is a type of steroid hormone, excessive or insufficient GC can affect pregnancy status and fetal development. Therefore, it is crucial to avoid unnecessary hormone exposure in the fetus while achieving the best therapeutic effect. This article reviewed the application and related adverse reactions of GC in pregnancy in recent years, aiming to provide reference for clinical practice.

  • Shaoneng XIANG
    World Clinical Drug. 2024, 45(5): 459-463.

    Corona virus disease 2019 (COVID-19) often presents with respiratory symptoms, and also leads to multiple organ failure, which can be life-threatening. Severe inflammation leads to cytokine storms, which are associated with organ dysfunction, disease severity, and mortality. Therefore, controlling high inflammatory response is crucial for the treatment of COVID-19. Glucocorticoid (GC) is one of the important drugs for controlling high inflammatory response. This article reviewed the safety and effectiveness of GC in the treatment of COVID-19 in recent years, aiming to provide reference for clinical practice.

  • Wen LUO, Jing CHEN
    World Clinical Drug. 2024, 45(5): 464-469.

    Glucocorticoid (GC) is widely used in the treatment of inflammation and immune system diseases, but long-term and high-dose use can cause various drug-related adverse reactions, including GC induced osteoporosis (GIO). Excessive GC can have harmful effects on bone cells, leading to impaired bone formation and resorption. Therefore, all long-term users of GC need to undergo regular fracture risk assessments. The article discussed the pathogenesis, clinical manifestations, fracture risk, and treatment strategies of GIO, to provide some reference for clinical practice.

  • Jiadan WANG, Ye ZHENG, Xiuhua PENG, Jian ZHANG, Xiaorong CHEN, Rong LIU
    World Clinical Drug. 2024, 45(5): 470-477.
    Objective

    To observe the efficacy and anti-inflammatory activity of Ruangan Zhuyu formula in the treatment of high-fat diet-induced nonalcoholic steatohepatitis (NASH) in mice, and to provide data support for its clinical application.

    Methods

    Forty-two C57BL/6 mice were randomly divided into model group, normal group, Silibinin Capsules group, Ruangan Zhuyu formula low, medium, and high dosage groups, seven mice in each group. The NASH model was induced in mice by feeding with high-fat diet for 14 weeks. After successful modelling, Ruangan Zhuyu formula each dose groups and the Silibinin Capsules group were given 1 ml drug solution every day by intragastric administration for 13 weeks on the basis of high-fat diet. The changes of body mass in each group were recorded. The mice were executed 2 weeks after the administration was stopped, and blood samples were collected to detect the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), laminin (LN), hyaluronic acid (HA), interleukin (IL)-2, IL-4, IL-6, IL-10 and interferon α(IFN-α). Hematoxylin-eosin (HE), oil-red, and Masson staining were used to observe the hepatic steatosis, fat droplet accumulation, and hepatic fibrosis.

    Results

    Compared with the model group, the body mass of mice in Ruangan Zhuyu formula group decreased significantly (P<0.05). The serum AST level in Ruangan Zhuyu formula high-dose group decreased significantly (P<0.05), the serum ALT level in Ruangan Zhuyu formula medium and high-dose groups decreased significantly (P<0.05), the level of IL-4, IL-6, IL-10 and IFN-α decreased significantly (P<0.05). The level of HA in Ruangan Zhuyu formula group decreased significantly (P<0.05). The results of HE, oil red and Masson staining showed that liver fibrosis and liver inflammation were significantly reduced in mice in Ruangan Zhuyu formula medium and high-dose groups.

    Conclusion

    Ruangan Zhuyu formula can effectively reduce the body mass of mice induced by high-fat diet, and improve the liver function and liver fibrosis of mice.

  • Shan XU, Pei DUAN, Min WANG, Lihua SONG
    World Clinical Drug. 2024, 45(5): 478-483.
    Objective

    To explore the curative effect of Yinzhihuang oral liquid on intrahepatic cholestasis of pregnancy (ICP).

    Methods

    A total of 110 ICP patients admitted to our hospital from June 2019 to June 2021 were selected and divided into the control group (ursodeoxycholic acid+adenosyl methionine treatment) and the study group (Yinzhihuang oral liquid was given on the basis of the control group) according to simple sequencing random method, with 55 patients in each group. The clinical efficacy, itching degree, phospholipid transfer protein (PLTP) level and maternal and infant outcomes were compared between the two groups.

    Results

    Compared with the control group, the total effective rate of the study group was significantly increased (P<0.05). After treatment, the pruritus score, PLTP and fibrinogen of ICP patients in both groups were significantly reduced, the prothrombin time was increased, and the improvement was more obvious in the study group (P<0.05). The total incidence of adverse outcomes in the study group and the control group was 10.91% and 27.27%, respectively, with statistical significance (P<0.05).

    Conclusion

    Yinzhihuang oral liquid combined with adenosyl-methionine and ursodeoxycholic acid has a better effect in the treatment of ICP patients, which can reduce the degree of pruritus and the expression level of serum PLTP, and improve the coagulation function and newborn outcome.

  • Junteng AN, Na ZHAO, Yanxin WANG
    World Clinical Drug. 2024, 45(5): 484-489.
    Objective

    To investigate the influences of fire needling combined with Huoxue Huayu decoction on the changes in nail fold microcirculation and the level of serum von Willebrand factor (vWF) of patients with psoriasis vulgaris (blood stasis syndrome).

    Methods

    120 patients with psoriasis vulgaris who were treated in our hospital from October 2021 to August 2022 were selected as the research objects. The patients were grouped into fire-needling group, decoction group, and combined group by random number table method, with 40 cases per group. The patients in the fire-needling group were treated with fire-needling on the target skin lesion area, Geshu, Ganshu and Shenshu points, and the patients in the decoction group were treated with self-made Huoxue Huayu decoction orally, and the patients in the combined group were treated with fire needling combined with Huoxue Huayu decoction. The morphological changes of nail fold microcirculation and serum vWF, antithrombin Ⅲ activity (AT-ⅢA), and plasminogen activator inhibitor-1 (PAI-1) levels were compared among the three groups.

    Results

    After treatment, compared with the fire-needling group and the decoction group, the psoriasis area and severity index (PASI), loop shape, fluid state, and peri-loop state, serum PAI-1 and vWF levels in the combined group were lower (P<0.05), and the serum AT-ⅢA level was higher (P<0.05). At 8 and 12 weeks after treatment, the PASI improvement rate of 75% in the combined group was higher than that of fire-needling group and decoction group (P<0.05).

    Conclusion

    Fire needling combined with Huoxue Huayu Decoction in the treatment of psoriasis vulgaris can improve the curative effect, reduce skin damage, and improve the morphological changes of nail fold microcirculation and blood hypercoagulability.

  • Juanzhi ZHAO, Chunhua LIU, Jing LI, Jiabi LIANG, Fenglei ZHU, Wenji LUO
    World Clinical Drug. 2024, 45(5): 490-496.
    Objective

    To investigate the population characteristics and clinical efficacy of Sheng Xuexiaoban capsules in the treatment of tumor chemotherapy-related thrombocytopenia (CIT) in the real word, and to observe its effectiveness and safety in a wide range of people, the rationality of clinical combination of drugs and the difference in efficacy of different combinations of drugs.

    Methods

    A retrospective study was conducted to select 2 812 CIT patients treated with Sheng Xuexiaoban capsules, and they were divided into four groups according to the combination of drugs, 1 522 patients in treatment group A (Sheng Xuexiaoban capsules alone), 719 patients in treatment group B (combined with recombinant human thrombopoietin injection), 786 patients in treatment group C (combined with interleukin-11), and 9 patients in treatment group D (combined with hexapopethanolamine tablets). The changes of platelet count and CIT grade before and after the treatment were compared.

    Results

    Compared with before treatment, platelet counts in treatment groups A, B and C all increased after treatment, and the difference was statistically significant (P<0.001). In different treatment stages, the difference of CIT grading among the four groups was statistically significant (P<0.05).

    Conclusion

    Sheng Xuexiaoban capsules can significantly improve the platelet level of tumor chemotherapy-related thrombocytopenia, especially in combination with recombinant human thrombopoietin injection and interleukin-11, the overall safety is good, worthy of clinical promotion and application.

  • Yuxin PENG, Zhixu ZHU, Dunming XIAO, Yan WEI
    World Clinical Drug. 2024, 45(5): 497-505.
    Objective

    To evaluate the economy of imaging bulk package contrast agents in CT rooms and explore the clinical application of bulk doses.

    Methods

    Based on contrast agent usage and medical insurance reimbursement of 1 169 patients in the database built by the research team and the hospital management information system, general statistical methods and decision tree model were used to analyze the impact of different specifications of contrast agents on the number of hospital scans. Economic evaluation was conducted by the minimum cost method. Additionally, qualitative interviews were conducted to explore the technical advantages and safety of imaging bulk package contrast agents.

    Results

    According to the average annual scans of 49 807 patients in the sample hospital, compared with the 100ml (400mg/ml) specification, the 500ml (400mg/ml) specification contrast agent saved an average of 29.60 s of examination time per person. This resulted in an annual increase of 3 890 scan patients, generating an additional revenue of approximately 3.01 million RMB for the hospital. The 500ml (400mg/ml) specification contrast agent, on average, saved medical insurance expenses for each hospital by 12.06—12.79 million RMB annually (a reduction of 52.19%—55.38%). The 500ml (400mg/ml) specification contrast agent also reduced medical waste by an average of 3 832 kg per year, saving waste disposal costs by 13 500 RMB. Qualitative interview results indicated that imaging bulk package contrast agents could save hospital resources to a certain extent and ensure safety at the current technological level.

    Conclusion

    With the continuous promotion of disease diagnosis-related groups payment models, imaging bulk package contrast agents have lower costs and can reduce resource waste, save nursing staff operation time. This can effectively reduce the economic burden on hospitals, improve the efficiency of medical insurance payment and hospital operation.

  • Qingming MO, Riting ZHU, Cuifang HAN
    World Clinical Drug. 2024, 45(5): 506-513.
    Objective

    To understand the occurrence of adverse events of linezolid in the real world and evaluate its medication safety, and mine adverse event signals of linezolid based on the data from the FDA Adverse Event Reporting System (FAERS) database, to provide reference for clinical drug treatment monitoring.

    Methods

    A total of 23 quarters of linezolid adverse event report data from the first quarter of 2018 to the third quarter of 2023 were screened from the FAERS database. After data cleaning, Medicines and Healthcare Products Regulatory Agency (MHRA) comprehensive method. The correlation of adverse events was measured using ROR values and proportional reporting ratio (PRR).

    Results

    A total of 26 075 adverse event reports with linezolid as the primary suspected drug were obtained, and 619 adverse event signals were mined. The adverse event signals of linezolid involved systemic diseases and reactions at the administration site, infections and infectious diseases, the blood and lymphatic system diseases, and various examinations. Adverse events with strong signals were found to be minimum inhibitory concentration [ROR 95% confidence interval (CI) lower limit=598.04, PRR=1 904.92], sideroblastic anemia (ROR 95% CI lower limit=515.20, PRR=1 108.32) and mediastinal effusion (ROR 95% CI lower limit=369.74, PRR=1 904.92). At the same time, adverse event signals such as trichoglossia (ROR 95% CI lower limit=97.39, PRR=144.43), choroiditis (ROR 95% CI lower limit=200.02, PRR=306.90) and cavernous transformation of portal vein (ROR 95% CI lower limit=180.90, PRR=507.98) were also identified that were not mentioned in the instructions.

    Conclusion

    Linezolid needs to be closely monitored for poor treatment efficacy and adverse events/reactions related to the blood system during clinical use. The results of this study also remind medical personnel to pay attention to new adverse event signals with strong signal values during drug treatment monitoring to ensure the safety and effectiveness of clinical medication.

  • Xiaozun YANG, Qiang LI
    World Clinical Drug. 2024, 45(5): 514-520.
    Objective

    To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer (NSCLC) patients.

    Methods

    This prospective, single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery. Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery. After discharge, patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter. The primary outcome was pathological remission rate. Secondary outcome measures were clinical response rate, disease-free survival (DFS), and overall survival (OS).

    Results

    The mean age of all enrolled patients was (59.84±7.14) years, including 18 males (72.00%) and 7 females (28.00%). The primary outcome indicated that 56% patients achieved significant pathological response, among which 24% achieved complete pathological response. The secondary outcome showed that 0, 60%, 36% and 4% patients achieved clinical complete response, partial response, disease stability and disease progression, and the overall objective response rate was 60%. The 1-year DFS was 79%, and the 1-year OS was 90%. There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS. Besides, The most common adverse events were alopecia (48%), fatigue (40%), nausea and vomiting (36%). Most of the adverse events were at grade 1 to 2, only a few were at grade 3 to 4.

    Conclusion

    Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.

News